Pricing Log in Create free account
Friday 6 November 2026 Export SNN’s income statement to Excel — free account

Smith & Nephew SNATS, Inc.

SNN Healthcare Medical Devices

Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024.

31.19 0.82 −2.56%
Market cap
$13.4B
P/E
38.9×
Fwd P/E
18.9×
Dividend yield
2.49%
F-score
7/9
Altman Z
3.49
Beneish M
−2.70
Dividend safety
61/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 6.93%

Capital & Financial Ratios $m

Size
Market Cap 13,400.00
Revenue ttm 10,498.22
Net income ttm 2,019.00
Free cash flow ttm 2,025.00
Net debt Q 2,458.00
Valuation
P/E 38.94 (above 35: high)
Forward P/E 18.90
Price / sales 1.37
Forward P/S Powerpack
Price / FCF 7.09
Price / book 2.77
Financial health
Current ratio Q 2.14 (at or above 1.5: strong)
Debt / equity Q 0.62
Interest coverage Q 18.83
Growth
Revenue growth Q +7.99% (above 0%: growing)
Operating income growth Q −3.83% (below 0%: shrinking)
EPS, this year +6.29%
EPS, next year A +8.21%
Revenue, next year A +39.80% (at or above 10%: strong)
EPS, past 5 yrs +7.02%
EPS, next 5 yrs A +8.71%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.6×, against a ten-year median of 1.9×; over the ten years it ranged from 1.2× in 2023 to 4.1× in 2017.
P/E against its own 10 years 93.00%
10-year low 10-year high
P/S against its own 10 years 32.86%
10-year low 10-year high
P/B against its own 10 years 39.57%
10-year low 10-year high
EV/Sales against its own 10 years 33.30%
10-year low 10-year high
EV/FCF against its own 10 years 3.26%
10-year low 10-year high

Dividends

Yield
2.49%
Annual rate
0.79
Payout ratio
—
Growth, 2017–25
+2.69%/yr
  1. 0.62 ’17
  2. 0.73 ’18 +19
  3. 0.73 ’19 −1
  4. 0.75 ’20 +3
  5. 0.75 ’21 +0
  6. 0.75 ’22 +0
  7. 0.75 ’23 +0
  8. 0.75 ’24 +0
  9. 0.76 ’25 +2
  10. 0.54 ’26e −29
paid forecast change on the year, % Powerpack

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 302 619 557 754
Receivables 1,333 1,415 1,429 1,520
Inventory 2,395 2,387 2,117 2,113
Other — — — —
4,030 4,421 4,103 4,387
2023 2024 2025 Q'26
Payables 1,055 1,128 1,177 1,249
ST’ Debt — — — —
Other 451 340 268 229
2,271 1,531 1,595 2,051

Compound Annual Growth %

10y 5y 3y
Sales 2.89% 6.21% 5.73%
Cash Flow 2.24% 6.57% 40.03%
Earnings 4.31% 6.89% 40.99%
Book Value 2.92% 0.04% 0.19%

Earnings Trends EPS, adjusted, against the consensus

Dec 2014 Estimate 0.51 Actual 0.51

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Mar 2014 0.36 0.35 Miss by 0.01
Jun 2014 0.38 0.41 Beat by 0.03
Sep 2014 0.39 0.39 Met by 0.00
Dec 2014 0.51 0.51 Met by 0.00

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 1.43
’24 — — — — 0.94
’23 — — — — 0.60
’22 — — — — 0.51
’21 — — — — 1.20
’20 — — — — 1.02
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 6,164
’24 — — — — 5,810
’23 — — — — 5,549
’22 — — — — 5,215
’21 — — — — 5,212
’20 — — — — 4,560
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 1,285
’24 — — — — 987
’23 — — — — 608
’22 — — — — 468
’21 — — — — 877
’20 — — — — 935
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — 260 — — —
’25 — 269 — 890 890
’24 — 66 — 606 606
’23 — (54) — 181 181
’22 — 34 — 110 110
’21 — 188 — 469 469
’20 — (115) — 492 492
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 4,669 4,765 4,904 5,138 4,560 5,212 5,215 5,549 5,810 6,164 10,498 +3.1% 8,617 9,069 9,565 +15.8%
Gross margin, % 72.76 73.81 73.53 73.96 69.39 70.40 70.47 68.82 69.64 68.01 70.52 (4.7) pt
EBT 1,062 879 781 743 246 586 235 290 498 779 964 (3.4%)
EBT margin, % 22.75 18.45 15.93 14.46 5.39 11.24 4.51 5.23 8.57 12.64 9.18 (10.1) pt
Net income 1,062 879 781 743 246 586 235 290 498 779 2,019 (3.4%)
Per share, $
Per share, $ Revenue 10.49 10.90 11.23 11.76 10.42 11.89 11.96 12.74 13.31 14.22 0.00 +3.4%
Earnings 1.76 1.76 1.52 1.37 1.03 1.20 0.51 0.60 0.94 1.44 0.82 (2.2%)
Cash flow 1.91 2.49 2.13 2.67 2.14 2.00 1.07 1.40 2.26 2.96 0.00 +5.0%
Capex (0.88) (0.86) (0.79) (0.93) (1.01) (0.93) (0.82) (0.98) (0.87) (0.91) 0.00 +0.4%
Free cash flow 1.03 1.63 1.34 1.74 1.12 1.07 0.25 0.42 1.39 2.05 0.00 +8.0%
Book value 8.89 10.63 11.17 11.76 12.07 12.70 12.06 11.98 12.06 12.20 0.00 +3.6%
Shares, m 445 437 437 437 438 439 436 436 437 434 447 (0.3%)
Valuation, ×
Valuation, × P/E 26.63 30.99 30.51 32.50 34.97 30.83 31.96 32.73 29.96 39.99 38.94 32.1
P/S 2.92 3.40 2.81 2.43 1.92 1.58 1.19 1.15 1.05 1.40 1.37 2.0
P/B 3.41 3.38 3.45 4.20 3.59 2.79 2.33 2.31 2.10 2.79 2.77 3.0
EV/Sales 3.24 3.67 2.97 2.62 2.09 1.74 1.42 1.34 1.30 1.65 1.60 2.2
EV/FCF 9.10 8.40 11.15 13.23 14.32 16.55 18.26 51.97 17.13 9.48 8.30 17.0
Cash, $m
Cash, $m Operating cash flow 849 1,090 931 1,168 935 877 468 608 987 1,285 3,118 +4.7%
Capex (392) (376) (347) (408) (443) (408) (358) (427) (381) (395) (1,093) +0.1%
Free cash flow 457 714 584 760 492 469 110 181 606 890 2,025 +7.7%
Balance, $m
Balance, $m Working capital 1,181 1,385 1,612 1,655 2,976 2,293 2,141 1,759 2,890 2,508 2,336 +8.7%
Net debt 1,464 1,254 936 1,698 1,591 1,558 2,362 2,017 2,639 2,620 2,458 +6.7%
Shareholders’ equity 3,958 4,644 4,874 5,141 5,279 5,568 5,259 5,217 5,265 5,289 5,180 +3.3%
Returns, %
Returns, % ROA 10.81 10.09 8.33 6.91 4.41 4.78 2.14 2.64 4.05 6.01 0.00 (4.8) pt
ROIC 9.23 9.90 9.28 7.45 2.68 5.20 3.69 3.67 5.20 6.27 0.00 (3.0) pt
ROE 19.79 17.83 13.93 11.98 8.60 9.66 4.12 5.02 7.86 11.84 0.00 (7.9) pt
People
People Employees 15,644 15,933 16,377 17,637 18,000 18,000 19,012 18,452 17,349 16,988 — +0.9%
Revenue/emp, $m 0.30 0.30 0.30 0.29 0.25 0.29 0.27 0.30 0.33 0.36 — +2.2%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2014

Smith & Nephew SNATS, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SNN Smith & Nephew SNATS, Inc. $13.4B 38.9× 18.9× +7.99% (above 0%: growing) −14.23% (below 0%: shrinking) +293.94% (above 0%: growing) 69.42% 0.00%
GKOS Glaukos Corporation $13.0B — (loss-making) — (loss-making) +58.03% (above 0%: growing) n/m +411.22% (above 0%: growing) 85.23% 0.39% Compare
PEN Penumbra, Inc. $12.7B 80.3× 68.7× +15.64% (above 0%: growing) −8.29% (below 0%: shrinking) −37.16% (below 0%: shrinking) 68.34% 12.37% Compare
GMED Globus Medical, Inc. $10.9B 19.5× 18.8× −0.69% (below 0%: shrinking) +19.32% (above 0%: growing) +10.10% (above 0%: growing) 69.50% 23.25% Compare
PODD Insulet Corporation $10.8B 25.2× 24.4× +19.21% (above 0%: growing) +64.06% (above 0%: growing) −29.81% (below 0%: shrinking) 75.07% 22.54% Compare
BIO.B Bio-Rad Laboratories, Inc. $10.3B 9.9× — +0.52% (above 0%: growing) n/m +8.07% (above 0%: growing) 50.06% (7.57%) Compare
BIO Bio-Rad Laboratories, Inc. $9.9B 9.7× 44.7× +0.52% (above 0%: growing) n/m +8.07% (above 0%: growing) 50.06% (7.57%) Compare
BRKR Bruker Corporation $8.9B — (loss-making) — (loss-making) +1.57% (above 0%: growing) n/m +278.74% (above 0%: growing) 49.12% (10.41%) Compare
TXG 10x Genomics $7.6B — (loss-making) — (loss-making) −12.65% (below 0%: shrinking) n/m −4.61% (below 0%: shrinking) 74.48% (12.95%) Compare
Median of peers $10.6B 19.5× 34.6× +1.05% +19.32% +8.07% 68.92% (3.59%)

All 149 Medical Devices stocks →

Smith & Nephew SNATS, Inc. (SNN) Latest News

25 Oct

Impact 4 · · Simply Wall St.
Impact 3 · · Simply Wall St.

24 Oct

Impact 3 · · TIKR

23 Oct

Impact 4 · · MT Newswires
Impact 3 · · TIKR
Impact 3 · · MT Newswires
Impact 3 · · MT Newswires

19 Oct

Impact 3 · · Investing.com

8 Oct

Impact 3 · · Zacks

6 Oct

Impact 4 · · MT Newswires
Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire

30 Sep

Impact 4 · · Zacks

23 Sep

Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire

22 Sep

Impact 4 · · GlobeNewswire

21 Sep

Impact 4 · · GlobeNewswire

18 Sep

Impact 3 ·

19 Aug

Impact 3 ·

18 Aug

Impact 4 ·
Impact 3 ·

17 Aug

Impact 3 ·

9 Aug

Impact 3 · · MarketBeat transcript

4 Aug

Impact 3 · · The Motley Fool transcript

29 Jul

Impact 4 ·

23 Jul

Impact 3 ·

21 Jul

Impact 3 ·

16 Jul

Impact 3 ·

15 Jul

Impact 3 ·

SNN metrics, ten years each

stockrow.com/SNN · Data as of Dec 31, 2014 · For information only; not investment advice. · © 2026 stockrow.com